bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2025-4-1261bekhterev-1263Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWБремя тардивной дискинезии у пациентов с психическими расстройствамиThe Burden of Tardive Dyskinesia in Patients with Mental Disordershttps://orcid.org/0000-0003-2266-9197ЗахаровД. В.ZakharovD. V.

Захаров Денис Валерьевич - д.м.н., главный научный сотрудник 

192019, Санкт-Петербург, ул. Бехтерева, д. 3

Denis V. Zakharov

St. Petersburg

zaharov_dv@mail.ruhttps://orcid.org/0000-0001-5618-4206НезнановН. Г.NeznanovN. G.

Незнанов Николай Григорьевич — д.м.н., профессор, заслуженный деятель науки РФ, директор ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Минздрава России, президент Российского общества психиатров, главный внештатный специалист-эксперт по психиатрии Росздравнадзора, президент Всемирной ассоциации динамической психиатрии

192019, Санкт-Петербург, ул. Бехтерева, д. 3

Nikolay G. Neznanov

St. Petersburg

nezn@bekhterev.ruНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. БехтереваРоссияV.M. Bekhterev National Medical Research Centre for Psychiatry and NeurologyRussian Federation2025090120265941824Copyright © Захаров Д.В., Незнанов Н.Г., 20262026Захаров Д.В., Незнанов Н.Г.Zakharov D.V., Neznanov N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/1263

Поздняя тардивная дискинезия (ТД) — серьёзное, часто инвалидизирующее двигательное расстройство, вызываемое препаратами, блокирующими дофаминовые рецепторы, в т.ч. нейролептиками. Распространенность ТД достаточно велика, однако, контроль факторов риска в теории позволит снизить вероятность развития ятрогении. ТД оказывает колоссальное негативное влияние на все сферы жизни пациента, включая физическое и психологическое самочувствие, социальную удовлетворенность и течение основного психического заболевания. В настоящее время не существует стандартного подхода к лечению. Вместе с тем в арсенале специалистов есть средства, существенно облегчающие состояние пациентов. Одним из таких препаратов является амантадина сульфат (ПК-мерц), показавший достаточную эффективность и безопасность у данной категории пациентов.

Tardive tardive dyskinesia (TD) is a serious, often disabling movement disorder caused by dopamine receptor blocking drugs, including antipsychotics. TD is quite common, but controlling risk factors can, in theory, reduce the likelihood of iatrogenic development. TD has a colossal negative impact on all areas of a patient's life, including physical and psychological well-being, social satisfaction, and the course of the underlying mental illness. Currently, there is no standard treatment approach. However, specialists have treatment options that can significantly alleviate the condition. One such drug is amantadine sulfate (PК-Merz), which has demonstrated sufficient efficacy and safety in this patient population.

тардивный синдромпоздняя тардивная дискинезияблокаторы дофаминовых рецепторовантипсихотикистигматизацияамантадинtardive syndrometardive dyskinesiadopamine receptor blockersantipsychoticsstigmatizationamantadineReferencesВайман Е.Э., Шнайдер Н.А., Незнанов Н.Г. и др. Патофизиологические механизмы, лежащие в основе антипсихотик-индуцированной тардивной дискинезии. Бюллетень сибирской медицины. 2019;18(4):169-184. https://doi.org/10.20538/1682-0363-2019-4-169-184Vayman EE, Shnayder NA, Neznanov NG, et al. Pathophysiological mechanisms underlying antipsychotic-induced tardive dyskinesia. Byulleten' sibirskoj mediciny. 2019;18(4):169-184. (In Russ.). https://doi.org/10.20538/1682-0363-2019-4-169-184Захаров Д.В., Буряк Ю.В., Михайлов В.А. Поздние (тардивные) нейролептик-индуцированные дискинезии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1):31–35. https://doi.org/10.17116/jnevro202212201131Zakharov DV, Buryak YuV, Mikhailov VA. Tardive (Late) Neuroleptic-Induced Dyskinesias. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2022;122(1):31–35. (In Russ.). https://doi.org/10.17116/jnevro202212201131Михайлов В.А., Захаров Д.В., Хубларова Л.А. Стратификация риска развития поздних лекарственно-индуцированных осложнений. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2017;(4):111-114.Khublarova LA, Zakharov DV, Mikhaylov VA. Stratification of the risk of developing tardive drug-induced complications. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2017;(4):111-114. (In Russ.).Хубларова Л.А., Захаров Д.В., Михайлов В.А. и др. Динамика показателей качества жизни пациентов с поздними нейролептическими дискинезиями в процессе ботулинотерапии. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2016;(4):86-91.Hublarova LA, Zakharov DV, Mikhailov VA, et al. Dynamics of the quality of life of patients with tardive form of neuroleptic dyskinesia during botulinum therapy. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2016;(4):86-91. (In Russ.).Ayyagari R, Goldschmidt D, Mu F, et al. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2022;20(1):154-166. https://doi.org/10.9758/cpn.2022.20.1.154Ayyagari R, Goldschmidt D, Mu F, et al. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2022;20(1):154-166. https://doi.org/10.9758/cpn.2022.20.1.154Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13(5):544-56. https://doi.org/10.1038/sj.mp.4002142Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13(5):544-56. https://doi.org/10.1038/sj.mp.4002142Barer Y, Ribalov R, Yaari A, et al. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis. J Clin Psychopharmacol. 2022;42(5):454-460. https://doi.org/10.1097/JCP.0000000000001597Barer Y, Ribalov R, Yaari A, et al. The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis. J Clin Psychopharmacol. 2022;42(5):454-460. https://doi.org/10.1097/JCP.0000000000001597Ben-Shlomo Y, Camfield L, Warner T; ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72(5):608-14. https://doi.org/10.1136/jnnp.72.5.608Ben-Shlomo Y, Camfield L, Warner T; ESDE collaborative group. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72(5):608-14. https://doi.org/10.1136/jnnp.72.5.608Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87(1024):132-41. https://doi.org/10.1136/pgmj.2010.103234Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87(1024):132-41. https://doi.org/10.1136/pgmj.2010.103234Burke RE, Fahn S, Jankovic J et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. https://doi.org/10.1212/wnl.32.12.1335Burke RE, Fahn S, Jankovic J et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. https://doi.org/10.1212/wnl.32.12.1335Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264-e278. https://doi.org/10.4088/JCP.16r10832.Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264-e278. https://doi.org/10.4088/JCP.16r10832.Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2020;18(4):493-506. https://doi.org/10.9758/cpn.2020.18.4.493Caroff SN. Recent Advances in the Pharmacology of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2020;18(4):493-506. https://doi.org/10.9758/cpn.2020.18.4.493Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32(3):198-208Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32(3):198-208Carroll B, Irwin DE. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. J Manag Care Spec Pharm. 2019;25(7):810-816. https://doi.org/10.18553/jmcp.2019.25.7.810Carroll B, Irwin DE. Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia. J Manag Care Spec Pharm. 2019;25(7):810-816. https://doi.org/10.18553/jmcp.2019.25.7.810Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:207-13. https://doi.org/10.1016/j.pnpbp.2012.10.018Cho CH, Lee HJ. Oxidative stress and tardive dyskinesia: pharmacogenetic evidence. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:207-13. https://doi.org/10.1016/j.pnpbp.2012.10.018Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-76. https://doi.org/10.1007/s13311-013-0222-5Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166-76. https://doi.org/10.1007/s13311-013-0222-5Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-25. https://doi.org/10.1176/appi.ajp.161.3.414Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414-25. https://doi.org/10.1176/appi.ajp.161.3.414Correll CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017;78(8):1136-1147. https://doi.org/10.4088/JCP.tv17016ah4cCorrell CU, Kane JM, Citrome LL. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment. J Clin Psychiatry. 2017;78(8):1136-1147. https://doi.org/10.4088/JCP.tv17016ah4cCrosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;2003(2):CD003467. https://doi.org/10.1002/14651858.CD003467Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;2003(2):CD003467. https://doi.org/10.1002/14651858.CD003467Del Dotto P, Pavese N, Gambaccini G. et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3):515-20. https://doi.org/10.1002/mds.1112Del Dotto P, Pavese N, Gambaccini G. et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3):515-20. https://doi.org/10.1002/mds.1112Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438-41. https://doi.org/10.1016/j.parkreldis.2010.04.007Esper CD, Freeman A, Factor SA. Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy. Parkinsonism Relat Disord. 2010;16(7):438-41. https://doi.org/10.1016/j.parkreldis.2010.04.007Faurbye Aб et al. Neurological symptoms in pharmagotherapy of psychoses. Acta Psychiatrica Scandinavica. 1964;40(1):10-27. https://doi.org/10.1111/j.1600-0447.1964.tb05731.xFaurbye Aб et al. Neurological symptoms in pharmagotherapy of psychoses. Acta Psychiatrica Scandinavica. 1964;40(1):10-27. https://doi.org/10.1111/j.1600-0447.1964.tb05731.xFreedman DX. Neurological Syndromes Associated with Antipsychotic Drug Use: A Special Report. Arch Gen Psychiatry. 1973;28(4):463–467. https://doi.org/10.1001/archpsyc.1973.01750340009001Freedman DX. Neurological Syndromes Associated with Antipsychotic Drug Use: A Special Report. Arch Gen Psychiatry. 1973;28(4):463–467. https://doi.org/10.1001/archpsyc.1973.01750340009001Frei K, Scott A, Caroff SN, Jankovic J, et al. Tardive dyskinesia versus tardive syndrome. What is in a name? Parkinsonism Relat Disord. 2025;133:107295. https://doi.org/10.1016/j.parkreldis.2025.107295Frei K, Scott A, Caroff SN, Jankovic J, et al. Tardive dyskinesia versus tardive syndrome. What is in a name? Parkinsonism Relat Disord. 2025;133:107295. https://doi.org/10.1016/j.parkreldis.2025.107295Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54(4):133-9.Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry. 1993;54(4):133-9.Haberfellner EM, Rittmannsberger H. Patientenwissen über tardive Dyskinesien [Patient knowledge regarding tardive dyskinesia]. Nervenarzt. 2006;77(3):333-7. German. https://doi.org/10.1007/s00115-005-1897-6Haberfellner EM, Rittmannsberger H. Patientenwissen über tardive Dyskinesien [Patient knowledge regarding tardive dyskinesia]. Nervenarzt. 2006;77(3):333-7. German. https://doi.org/10.1007/s00115-005-1897-6Jain G. Rapid response of disabling tardive dyskinesia to amantadine: a case report. Prim Care Companion CNS Disord. 2011;13(3):PCC.10l01098. https://doi.org/10.4088/PCC.10l01098Jain G. Rapid response of disabling tardive dyskinesia to amantadine: a case report. Prim Care Companion CNS Disord. 2011;13(3):PCC.10l01098. https://doi.org/10.4088/PCC.10l01098Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States. J Patient Rep Outcomes. 2023;7(1):122. https://doi.org/10.1186/s41687-023-00658-9Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States. J Patient Rep Outcomes. 2023;7(1):122. https://doi.org/10.1186/s41687-023-00658-9Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473-81. https://doi.org/10.1001/archpsyc.1982.04290040069010Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39(4):473-81. https://doi.org/10.1001/archpsyc.1982.04290040069010Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-10. https://doi.org/10.1192/bjp.158.4.503Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-10. https://doi.org/10.1192/bjp.158.4.503Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. https://doi.org/10.1056/NEJMoa051688Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23. https://doi.org/10.1056/NEJMoa051688Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014 Aug;29(9):1125-33. https://doi.org/10.1002/mds.25909Mahmoudi S, Lévesque D, Blanchet PJ. Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model. Mov Disord. 2014 Aug;29(9):1125-33. https://doi.org/10.1002/mds.25909McEvoy JP. Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia. J Clin Psychiatry. 2019;80(6):NU18041BR2C. https://doi.org/10.4088/JCP.NU18041BR2CMcEvoy JP. Psychosocial Implications of Tardive Dyskinesia in Patients With Mood Disorders Versus Schizophrenia. J Clin Psychiatry. 2019;80(6):NU18041BR2C. https://doi.org/10.4088/JCP.NU18041BR2CMoraru E, Schnider P, Wimmer A et al. Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety. 2002;16(3):100-3. https://doi.org/10.1002/da.1003Moraru E, Schnider P, Wimmer A et al. Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety. 2002;16(3):100-3. https://doi.org/10.1002/da.1003Müller J, et al. Social anxiety and avoidance in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:500–505.Müller J, et al. Social anxiety and avoidance in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72:500–505.Neznanov N, Vasilyeva A. Psychodynamic aspects of self-stigamtization. European Psychiatry. 2011;72:123–129. https://doi.org/10.1016/S0924-9338(12)75097-6Neznanov N, Vasilyeva A. Psychodynamic aspects of self-stigamtization. European Psychiatry. 2011;72:123–129. https://doi.org/10.1016/S0924-9338(12)75097-6Niemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018;78(5):525-541. https://doi.org/10.1007/s40265-018-0874-xNiemann N, Jankovic J. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018;78(5):525-541. https://doi.org/10.1007/s40265-018-0874-xParacka L, Wegner F, Escher C, Klietz M, de Zwaan M, Abdallat M, Saryyeva A, Krauss JK. Body Concept and Quality of Life in Patients with Idiopathic Dystonia. Brain Sci. 2020;10(8):488. https://doi.org/10.3390/brainsci10080488Paracka L, Wegner F, Escher C, Klietz M, de Zwaan M, Abdallat M, Saryyeva A, Krauss JK. Body Concept and Quality of Life in Patients with Idiopathic Dystonia. Brain Sci. 2020;10(8):488. https://doi.org/10.3390/brainsci10080488Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. J Psychopharmacol. 2019;33(10):1187-1198. https://doi.org/10.1177/0269881119862535Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review. J Psychopharmacol. 2019;33(10):1187-1198. https://doi.org/10.1177/0269881119862535Ray S, Pal PK, Yadav R. Non-Motor Symptoms in Cervical Dystonia: A Review. Ann Indian Acad Neurol. 2020;23(4):449-457. https://doi.org/10.4103/aian.AIAN_27_20Ray S, Pal PK, Yadav R. Non-Motor Symptoms in Cervical Dystonia: A Review. Ann Indian Acad Neurol. 2020;23(4):449-457. https://doi.org/10.4103/aian.AIAN_27_20Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry. 2019;64(6):388-399. https://doi.org/10.1177/0706743719828968Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment Recommendations for Tardive Dyskinesia. Can J Psychiatry. 2019;64(6):388-399. https://doi.org/10.1177/0706743719828968Rinnerthaler M, Mueller J, Weichbold V, Wenning GK, Poewe W. Social stigmatization in patients with cranial and cervical dystonia. Mov Disord. 2006;21(10):1636-40. https://doi.org/10.1002/mds.21049Rinnerthaler M, Mueller J, Weichbold V, Wenning GK, Poewe W. Social stigmatization in patients with cranial and cervical dystonia. Mov Disord. 2006;21(10):1636-40. https://doi.org/10.1002/mds.21049Sakata M, Ito H. Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge. Brain Nerve. 2022;74(5):571-574. https://doi.org/10.11477/mf.1416202082Sakata M, Ito H. Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge. Brain Nerve. 2022;74(5):571-574. https://doi.org/10.11477/mf.1416202082Sandyk R, Kay SR. Suicidal behavior and tardive dyskinesia. Int J Neurosci. 1991;57(3-4):269-71. https://doi.org/10.3109/00207459109150701Sandyk R, Kay SR. Suicidal behavior and tardive dyskinesia. Int J Neurosci. 1991;57(3-4):269-71. https://doi.org/10.3109/00207459109150701Schonecker M. Paroxysmale Dyskinesen als Megaphenwirung [ Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt. 1957;28(12):550-3Schonecker M. Paroxysmale Dyskinesen als Megaphenwirung [ Paroxysmal dyskinesia as the effect of megaphen]. Nervenarzt. 1957;28(12):550-3Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-69. https://doi.org/10.1055/s-2007-971169Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159-69. https://doi.org/10.1055/s-2007-971169Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186–90. https://doi.org/10.1136/jnnp.68.2.186Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: A clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186–90. https://doi.org/10.1136/jnnp.68.2.186Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601-16. https://doi.org/10.1016/B978-0-444-52014-2.00043-4Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol. 2011;100:601-16. https://doi.org/10.1016/B978-0-444-52014-2.00043-4Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-30. https://doi.org/10.1016/B978-0-12-381328-2.00009-2.Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-30. https://doi.org/10.1016/B978-0-12-381328-2.00009-2.Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205-15. https://doi.org/10.1002/mds.25107Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205-15. https://doi.org/10.1002/mds.25107Torres JAKL, Rosales RL. Nonmotor Symptoms in Dystonia. Int Rev Neurobiol. 2017;134:1335-1371. https://doi.org/10.1016/bs.irn.2017.05.003Torres JAKL, Rosales RL. Nonmotor Symptoms in Dystonia. Int Rev Neurobiol. 2017;134:1335-1371. https://doi.org/10.1016/bs.irn.2017.05.003Vasan S., Padhy R.K. Tardive Dyskinesia. In StatPearls Publishing; 2025.Vasan S., Padhy R.K. Tardive Dyskinesia. In StatPearls Publishing; 2025.Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701-15. https://doi.org/10.1093/schbul/18.4.701Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull. 1992;18(4):701-15. https://doi.org/10.1093/schbul/18.4.701Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord. 2013;28(7):914-20. https://doi.org/10.1002/mds.25501Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord. 2013;28(7):914-20. https://doi.org/10.1002/mds.25501

The authors declare that there are no conflicts of interest present.